Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Merus NV (DE:2GH)
FRANKFURT:2GH
Merus (2GH) Stock Price & Analysis
1 Followers
2GH Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€16.40 - €48.60
Previous Close€37.4
Volume0.00
Average Volume (3M)290.00
Market Cap
€2.21B
Enterprise Value€1.85B
Total Cash (Recent Filing)$388.57M
Total Debt (Recent Filing)$12.11M
Price to Earnings (P/E)N/A
Beta0.05
Next Earnings
May 06, 2024EPS Estimate
-€0.76Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding57,878,284
10 Day Avg. Volume0
30 Day Avg. Volume290
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)6.85
Price to Sales (P/S)52.33
Price to Cash Flow (P/CF)-16.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue40.60
Enterprise Value/Gross Profit44.59
Enterprise Value/Ebitda-12.15
Forecast
1Y Price Target
€57.67Price Target Upside50.97% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Merus News
Bulls Say, Bears Say
Bulls Say
Analyst RatingsAnalyst raises price target to $65, reflecting sales potential for Peto in head and neck cancer treatment.
Clinical TrialsPositive petosemtamab data in 2Q would further validate the company's bispecific antibody platform.
Financial StabilityThe company has a cash runway through 2027, ensuring financial stability for upcoming operations.
Bears Say
Competitive Position‘129 has not shown a differentiated safety or efficacy profile, making it challenging to enter a market where a new therapy requires distinct advantages.
Financial ValuationAnalysts have lowered the pipeline value for ‘129 to $800 million as additional data is awaited to validate its potential, reflecting decreased confidence in its market prospects.
Safety ConcernsThe market opportunity for ‘129 could be limited given an unfavorable safety profile to-date, with high rates of interstitial lung disease (ILD) and venous thromboembolic events (VTE).
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
2.12% Other Institutional Investors
97.88% Public Companies and
Individual Investors
2GH FAQ
What was Merus NV’s price range in the past 12 months?
Merus NV lowest stock price was €16.40 and its highest was €48.60 in the past 12 months.
What is Merus NV’s market cap?
Currently, no data Available
When is Merus NV’s upcoming earnings report date?
Merus NV’s upcoming earnings report date is May 06, 2024 which is in 7 days.
How were Merus NV’s earnings last quarter?
Merus NV released its earnings results on Feb 28, 2024. The company reported -€0.981 earnings per share for the quarter, missing the consensus estimate of -€0.729 by -€0.251.
Is Merus NV overvalued?
According to Wall Street analysts Merus NV’s price is currently Undervalued.
Does Merus NV pay dividends?
Merus NV does not currently pay dividends.
What is Merus NV’s EPS estimate?
Merus NV’s EPS estimate is -€0.76.
How many shares outstanding does Merus NV have?
Currently, no data Available
What happened to Merus NV’s price movement after its last earnings report?
Merus NV reported an EPS of -€0.981 in its last earnings report, missing expectations of -€0.729. Following the earnings report the stock price went down -0.897%.
Which hedge fund is a major shareholder of Merus NV?
Among the largest hedge funds holding Merus NV’s share is Deerfield Management Company, LP. It holds Merus NV’s shares valued at 83M.
---
Merus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€57.67 (50.97% Upside)
€57.67 (50.97% Upside)
Blogger Sentiment
Bullish
DE:2GH Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
122.53%
12-Months-Change
Fundamentals
Return on Equity
-51.36%
Trailing 12-Months
Asset Growth
20.69%
Trailing 12-Months
Company Description
Merus NV
Merus NV is a clinical-stage immune-oncology company, which engages in the discovery and development of bi-specific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg on June 16, 2003 and is headquartered in Utrecht, Netherlands.
---
2GH Stock 12 Months Forecast
Average Price Target
€57.67
▲(50.97% Upside)
Technical Analysis
Best Analysts Covering 2GH
1 Year
1 Year Success Rate
9/12 ratings generated profit
1 Year Average Return
+53.42%
reiterated a buy rating 2 months ago
Copying Andrew Fein's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +53.42% per trade.
---